Clinical outcomes with definitive surgery or radiotherapy after neoadjuvant immunochemotherapy in stage II-III NSCLC: Full cohort pragmatic analysis.

医学 肿瘤科 放射治疗 阶段(地层学) 队列 新辅助治疗 内科学 外科 癌症 乳腺癌 古生物学 生物
作者
Jie He,Zhenlin Yang,Shuaibo Wang,Xiangyang Yu,Xiaotong Guo,Jianjiao Ni,Linhai Zhu,Jian Hu,Guoqing Zhang,Chun Chen,Chun Chen,Guangjian Zhang,Bin Hu,Cui Gao,Lipin Liu,Pan Chen,Huajie Xing,Chuanbao Xia
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl): 8059-8059
标识
DOI:10.1200/jco.2025.43.16_suppl.8059
摘要

8059 Background: Recently, several landmark randomized controlled trials on neoadjuvant immunochemotherapy (NIC) have significantly changed the treatment paradigm for locally advanced NSCLC. However, 8.8-19.0% of patients (pts) receiving NIC did not undergo surgery due to various reasons. The treatment strategies and clinical outcomes following NIC for stage II-III NSCLC, encompassing both surgical and non-surgical approaches, remain unclear. Methods: We conducted a multicenter, retrospective cohort study involving stage II-III (T1-4N0-2) pts who underwent radical surgery or radiotherapy after NIC in routine clinical practice across 12 medical centers in China between January 2018 and December 2023. For pts receiving radical radiotherapy, we documented the reasons for non-surgical management, and planned surgical procedures. Propensity score matching (PSM) was performed based on age, gender, smoking history, clinical stage, and histology to balance the clinicopathologic characteristics. The primary outcomes were progression free survival (PFS) and overall survival (OS). Results: 967 pts were included: 683 (70.6%) underwent surgery and 284 (29.4%) received radiotherapy. Reasons for radiotherapy after NIC included potentially resectable but declined surgery after shared decision-making (65.5%, 186/284), functionally unresectable (14.4%, 41/284), and technically unresectable (20.1%, 57/284), respectively. At the database lock (November 24, 2024; median follow-up: 23.3 months), PFS (HR: 0.32, 95% CI: 0.23-0.44, p<0.001) and OS (HR: 0.41, 95% CI: 0.26-0.66, p<0.001) were significantly improved in pts undergoing surgery after PSM. PFS across most key subgroups favored surgery: stage IIIA (HR: 0.34, 95% CI: 0.21-0.55, p <0.001), stage IIIB (HR: 0.39, 95% CI: 0.24-0.63, p <0.001), (planned) pneumonectomy (HR: 0.47, 95% CI: 0.26-0.85, p=0.013) and (planned) lobectomy (HR: 0.24, 95% CI: 0.13-0.45, p<0.001). However, the pts planned for pneumonectomy in radiotherapy group exhibited similar OS compared to those undergoing pneumonectomy. Conclusions: Among pts with locally advanced NSCLC treated with NIC, radical surgery demonstrated long-term clinical benefit. Subgroups N (S) N (R) HR (95% CI) p-value PFS All patients 365 183 0.32 (0.23, 0.44) <0.001 Disease stage II 34 17 0.05 (0.01, 0.24) <0.001 IIIA 175 89 0.34 (0.21, 0.55) <0.001 IIIB 142 76 0.39 (0.24, 0.63) <0.001 (Planned) Surgery Pneumonectomy 66 66 0.47 (0.26, 0.85) 0.013 Left pneumonectomy 46 46 0.52 (0.26, 1.04) 0.066 Lobectomy 106 54 0.24 (0.13, 0.45) <0.001 OS All patients 365 183 0.41 (0.26, 0.66) <0.001 Disease stage II 34 17 0.08 (0.01, 0.44) 0.004 IIIA 175 89 0.60 (0.28, 1.25) 0.17 IIIB 142 76

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
可爱春天发布了新的文献求助10
1秒前
杨小坤完成签到 ,获得积分10
1秒前
1秒前
了晨发布了新的文献求助10
1秒前
dabai发布了新的文献求助10
2秒前
李健的应助被Tqs采纳,获得10
2秒前
4秒前
洁净糖豆发布了新的文献求助10
4秒前
4秒前
4秒前
yzy发布了新的文献求助10
5秒前
未见山发布了新的文献求助10
5秒前
5秒前
情怀的应助被潇湘阁我爱吃采纳,获得10
5秒前
cockcrow发布了新的文献求助10
5秒前
6秒前
英俊的铭的应助被yk采纳,获得10
6秒前
CodeCraft的应助被可爱春天采纳,获得10
7秒前
7秒前
stc发布了新的文献求助10
7秒前
芯子发布了新的文献求助10
7秒前
Akim的应助被wangxinlei采纳,获得10
8秒前
8秒前
9秒前
阿尼完成签到,获得积分10
9秒前
安稳发布了新的文献求助10
10秒前
悦耳笑晴完成签到,获得积分20
10秒前
丰富黄豆发布了新的文献求助10
10秒前
11秒前
LL发布了新的文献求助10
11秒前
秋风的应助被cockcrow采纳,获得10
12秒前
white完成签到,获得积分10
13秒前
胡萝贝发布了新的文献求助10
14秒前
15秒前
15秒前
未见山完成签到,获得积分10
16秒前
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153710
求助须知:如何正确求助?哪些是违规求助? 9550475
关于积分的说明 21698625
捐赠科研通 7742521
什么是DOI,文献DOI怎么找? 3425571
关于科研通互助平台的介绍 2550735
邀请新用户注册赠送积分活动 2469211